| Name | Title | Contact Details |
|---|
Established in 1968, Providence Community Health Centers, Inc. is the largest primary health care provider in Providence, Rhode Island. In addition to eight health centers, we also operate a school-based program, and a dental clinic serving children under the age of 19 and pregnant women. PCHC is a non-profit health care organization and the only Federally Qualified Heath Center (FQHC) in Providence. We have recruited some of the area`s most prestigious physicians and empowered them to make a difference providing quality care to more than 50,000+ residents of Providence and its surrounding areas. As we continue to grow our network of neighborhood-based clinics, PCHC is seeking physicians to join our team. Our services include: Family Practice, Internal Medicine, Pediatrics, Obstetrics, Gynecology, Behavioral Health, Dental Care and Express Care (urgent care) alongside with selected specialty services.
Our mission as an organization is to serve our neighbors as expert, caring partners in their health. We do this by creating innovative, effective, affordable systems of care that our neighbors value. This is our promise to you. We call it The ChristianaCare Way. ChristianaCare has the most advanced health care technology available to help meet your needs. But more important than the technology is our commitment to partner with you to meet your individual needs. We want to care for you and help you live the healthy life you want to live.
Ascend Healthcare is a residential treatment facility for teens struggling with mental health and addiction issues. They provide evidence-based therapies, experiential therapies, and a unique clinical approach to help their clients. Their focus on fami...
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
PaloDEx Group Oy operates in the international healthcare market, focusing on X-ray technology applications used in dental imaging. By offering high-quality imaging solutions that help in making the correct treatment decisions and in improving the level